Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab treatment withdrawal and retreatment study in non-radiographic axial spondyloarthritis remission
MOH_2022-11-21_012188Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of secukinumab in non-radiographic axial spondyloarthritis (nr-axSpA) (4 arms), sponsored by Novartis. Started Jan 2023; status: recruiting.
02
Drugs
secukinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on MOH_2022-11-21_012188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-21_012188.